Caerulomycin A suppresses the differentiation of naïve T cells and alleviates the symptoms of experimental autoimmune encephalomyelitis

References

• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129:1953–1971.
   PubMed Web of Science ®Google Scholar
• Hafler DA. Multiple sclerosis. J Clin Invest. 2004;113:788–794.
   PubMed Web of Science ®Google Scholar
• Pierson E, Simmons SB, Castelli L, et al. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev. 2012;248:205–215.
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139–145.
   PubMed Web of Science ®Google Scholar
• Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006;60:12–21.
   PubMed Web of Science ®Google Scholar
• Slavin A, Kelly-Modis L, Labadia M, et al. Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity. 2010;43:504–513.
   PubMed Web of Science ®Google Scholar
• Voskuhl RR, Martin R, Bergman C, et al. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity. 1993;15:137–143.
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162:1–11.
   PubMed Web of Science ®Google Scholar
• Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009;9:393–407.
   PubMed Web of Science ®Google Scholar
• McWilliams IL, Rajbhandari R, Nozell S, et al. STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE. J Neuroinflammation. 2015;12:128.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–240.
   PubMed Web of Science ®Google Scholar
• Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995;16:34–38.
   PubMedGoogle Scholar
• Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–1141.
   PubMed Web of Science ®Google Scholar
• Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol. 2008;255(Suppl 1):3–11.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239–248.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.
   PubMed Web of Science ®Google Scholar
• Sacks SH. Rapamycin on trial. Nephrol Dial Transplant. 1999;14:2087–2089.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Tang Q. Therapeutic vaccination using CD4 + CD25+ antigen-specific regulatory T cells. Proc Nat Acad Sci USA. 2004;101(Suppl 2):14622–14626.
   PubMed Web of Science ®Google Scholar
• Shevach EM. Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 2004;50:2721–2724.
   PubMed Web of Science ®Google Scholar
• Zhou X, Kong N, Zou H, et al. Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity. 2011;44:43–50.
   PubMed Web of Science ®Google Scholar
• Singla AK, Mayilraj S, Kudo T, et al. Actinoalloteichus spitiensis sp. nov., a novel actinobacterium isolated from a cold desert of the Indian Himalayas. Int J Syst Evol Microbiol. 2005;55:2561–2564.
   PubMed Web of Science ®Google Scholar
• Funk A, Divekar PV. Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. I. Production, isolation, assay, and biological properties. Can J Microbiol. 1959;5:317–321.
   PubMed Web of Science ®Google Scholar
• Chatterjee DK, Raether W, Iyer N, et al. Caerulomycin, an antifungal antibiotic with marked in vitro and in vivo activity against Entamoeba histolytica. Z Parasitenkd. 1984;70:569–573.
   PubMed Web of Science ®Google Scholar
• Gurram RK, Kujur W, Maurya SK, et al. Caerulomycin A enhances transforming growth factor-beta (TGF-beta)-Smad3 protein signaling by suppressing interferon-gamma (IFN-gamma)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs). J Biol Chem. 2014;289:17515–17528.
   PubMed Web of Science ®Google Scholar
• Cristalli G, Franchetti P, Grifantini M, et al. 2,2′-Bipyridyl-6-carboxamidoximes with potential antitumor and anti microbial properties. Formaco Sci. 1986;41:499–507.
   PubMedGoogle Scholar
• Yadav VK, Kumar A, Mann A, et al. Engeenered reversal of drug resistance in cancer cells metastases suppressor factors as change agents. Nucleic Acids Res. 2014;42:764–773.
   PubMed Web of Science ®Google Scholar
• Kaur S, Srivastava G, Sharma AN, et al. Novel immunosuppressive agent caerulomycin a exerts its effect by depleting cellular iron content. Br J Pharmacol. 2015;172:2286–2299.
   PubMed Web of Science ®Google Scholar
• Singla AK, Gurram RK, Chauhan A, et al. Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. Transplantation. 2014;97:e57–e59.
   PubMed Web of Science ®Google Scholar
• Singla AK, Gurram RK, Chauhan A, et al. Caerulomycin A suppresses immunity by inhibiting T cell activity. PLoS One. 2014;9:e107051.
   PubMed Web of Science ®Google Scholar
• Allegretta M, Nicklas JA, Sriram S, et al. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 1990;247:718–721.
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE, Trotter JL, Lauber J, et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest. 1998;101:725–730.
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Cortese I, Wandinger KP, et al. CD4 + CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest. 2001;108:1185–1194.
   PubMed Web of Science ®Google Scholar
• Scholz C, Patton KT, Anderson DE, et al. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol. 1998;160:1532–1538.
   PubMed Web of Science ®Google Scholar
• Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol. 2003;14:2402–2410.
   PubMed Web of Science ®Google Scholar
• Korideck H, Peterson JD. Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma. J Pharmacol Exp Ther. 2009;329:882–889.
   PubMed Web of Science ®Google Scholar
• Kujur W, Gurram RK, Haleem N, et al. Caerulomycin A inhibits Th2 cell activity: a possible role in the management of asthma. Sci Rep. 2015;5:15396.
   PubMed Web of Science ®Google Scholar
• Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann NY Acad Sci. 2010;1183:211–221.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Grubeck-Loebenstein B, et al. Imbalance of regulatory T cells in human autoimmune diseases. Immunology. 2006;117:289–300.
   PubMed Web of Science ®Google Scholar
• Palmer MT, Weaver CT. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol. 2010;11:36–40.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21:1105–1111.
   PubMed Web of Science ®Google Scholar
• Devarajan P, Chen Z. Autoimmune effector memory T cells: the bad and the good. Immunol Res. 2013;57:12–22.
   PubMed Web of Science ®Google Scholar
• Kawakami N, Odoardi F, Ziemssen T, et al. Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. J Immunol. 2005;175:69–81.
   PubMed Web of Science ®Google Scholar
• Pugliese A, Reijonen HK, Nepom J, et al. Recurrence of autoimmunity in pancreas transplant patients: research update. Diabetes Manage. 2011;1:229–238.
   PubMedGoogle Scholar
• Walter U, Santamaria P. CD8+ T cells in autoimmunity. Curr Opin Immunol. 2005;17:624–631.
   PubMed Web of Science ®Google Scholar
• Stucker F, Ackermann D. Immunosuppressive drugs – how they work, their side effects and interactions. Ther Umsch. 2011;68(12):679–686.
   PubMedGoogle Scholar